Trial · NCT03228680
Outcomes39
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
21 to 39 of 39
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Circulating Levels of Endocrine Parameters (Follicle-stimulating Hormone [FSH], Luteinising Hormone [LH]) at End-of-stimulation | End-of-stimulation (up to 20 stimulation days) | The FAS comprised of all randomized and exposed participants. | IU/L | MEDIAN |
| SECONDARY | Circulating Levels of Endocrine Parameter (Estradiol) on Stimulation Day 6 | At Day 6 of stimulation | The FAS comprised of all randomized and exposed participants. | pmol/L | MEDIAN |
| SECONDARY | Circulating Levels of Endocrine Parameter (Estradiol) at End-of-stimulation | End-of-stimulation (up to 20 stimulation days) | The FAS comprised of all randomized and exposed participants. | pmol/L | MEDIAN |
| SECONDARY | Circulating Levels of Endocrine Parameter (Progesterone) on Stimulation Day 6 | At Day 6 of stimulation | The FAS comprised of all randomized and exposed participants. | nmol/L | MEDIAN |
| SECONDARY | Circulating Levels of Endocrine Parameter (Progesterone) at End-of-stimulation | End-of-stimulation (up to 20 stimulation days) | The FAS comprised of all randomized and exposed participants. | nmol/L | MEDIAN |
| SECONDARY | Circulating Levels of Endocrine Parameters (Inhibin A) on Stimulation Day 6 | At Day 6 of stimulation | The FAS comprised of all randomized and exposed participants. | ng/L | MEDIAN |
| SECONDARY | Circulating Levels of Endocrine Parameters (Inhibin A) at End-of-stimulation | End-of-stimulation (up to 20 stimulation days) | The FAS comprised of all randomized and exposed participants. | ng/L | MEDIAN |
| SECONDARY | Circulating Levels of Endocrine Parameters (Inhibin B) on Stimulation Day 6 | At Day 6 of stimulation | The FAS comprised of all randomized and exposed participants. | ng/L | MEDIAN |
| SECONDARY | Circulating Levels of Endocrine Parameters (Inhibin B) at End-of-stimulation | End-of-stimulation (up to 20 stimulation days) | The FAS comprised of all randomized and exposed participants. | ng/L | MEDIAN |
| SECONDARY | Number of Stimulation Days | End-of-stimulation (up to 20 stimulation days) | The safety analysis set comprised of all randomized and exposed participants. | Days | MEAN |
| SECONDARY | Total Gonadotropin Dose of FE 999049 | End-of-stimulation (up to 20 stimulation days) | The safety analysis set comprised of all randomized and exposed participants. | μg | MEAN |
| SECONDARY | Total Gonadotropin Dose of FOLLISTIM | End-of-stimulation (up to 20 stimulation days) | The safety analysis set comprised of all randomized and exposed participants. | IU | MEAN |
| SECONDARY | Number of Participants With Adverse Events (AEs) Stratified by Intensity | From signed informed consent up to 5-6 weeks after transfer | The safety analysis set comprised of all randomized and exposed participants. | Participants | NUMBER |
| SECONDARY | Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Clinical Chemistry Parameters at End-of-stimulation | End-of-stimulation (up to 20 stimulation days) | The safety analysis set comprised of all randomized and exposed participants. | participants | NUMBER |
| SECONDARY | Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Hematology Parameters at End-of-stimulation | End-of-stimulation (up to 20 stimulation days) | The safety analysis set comprised of all randomized and exposed participants. | participants | NUMBER |
| SECONDARY | Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Clinical Chemistry Parameters at End-of-trial | Up to 5-6 weeks after transfer | The safety analysis set comprised of all randomized and exposed participants. | participants | NUMBER |
| SECONDARY | Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Hematology Parameters at End-of-trial | Up to 5-6 weeks after transfer | The safety analysis set comprised of all randomized and exposed participants. | participants | NUMBER |
| SECONDARY | Frequency and Intensity of Injection Site Reactions | End-of-stimulation (up to 20 stimulation days) | The safety analysis set comprised of all randomized and exposed participants. | events | NUMBER |
| SECONDARY | Technical Malfunctions of the Administration Pens | End-of-stimulation (up to 20 stimulation days) | The safety analysis set comprised of all randomized and exposed participants. | percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03228680/outcomes?page=2